![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTRXn3bHfjpTuGcDP0Z7ga17DSt8oV-6vx5dx49U5A9hks9_SliL8nAkoyVWC5OWmchDL1fKMdrILQhn6SneJ-0_Jo_p6pF8bse9enhwcnvvoyksvLgLOblpMHpbpdrAjucsyu6-ihnz4/s320/TEVA+Ceo.jpg)
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhGX5IU0-1JHl46bSnaZZu5aAZicn2ij1xBKt7h-q2ftTvdPRRpWGzKdIxDCU4ML-CdZEv_8jIE1_dEGPQqGbDJRpOjApgjEVK87pAgAOJjFf2-dcmmt2Yh0iyZj-YCmg0It92uA_7s5QI/s200/aLevin.jpg)
When Levin succeeds Shlomo Yanai in May, he is going to need those skills, and then some.
Teva is a company in transition. Once a plucky upstart, it’s now an industry behemoth, among the world’s largest drug makers with a market capitalization exceeding $35 billion. And the tables have turned, as firms in India grab share playing Teva’s game – selling low-priced generic drugs. (Más)
Ver:
No hay comentarios:
Publicar un comentario